

TABLE 1. Comparative presentation of the three landmark studies on Very Late Relapses in Hodgkin Lymphoma

	Brockelman PJ et al.	Vassilakopoulos TP et al.	Andersen MD et al.			
Patients in CR1 > 5 years	4935	1143	2424*			
Number of VLR	141	66	58			
Median follow-up time, years (range)	10.3	13.8 (5-47)	16.0 (5.8-24.3)			
VLRs beyond 20 years [# (%)]	1? (<1%)	8 (12%)	0			
Time to latest VLR (years from diagnosis)	~20.5	35.1	18.9			
Median age at initial diagnosis, years (range)	33 (17-70)	31 (IQR: 23-44)	38 (15-93)			
Gender, male (% of initial population)	54	54	59			
Initial treatment (% of initial population)						
CT alone	16	26	NR			
CT + RT	80	74	NR			
RT alone	4	0	7			
Chemotherapy Regimen (% of initial population)						
ABVD and equivalents	51	91	77			
MOPP and equivalents	0	9	5			
BEACOPP-based	45	0	7			
Histologic Subtype (%)	All pts	VLRs	All pts	VLRs	All pts	VLRs
NLPHL (% of total)	0	0	6	9	6	24
cHL (by definition 100%)	100	100	100	100	100	100
NS (% among cHL)	63	47	69	44	59	55
MC (% among cHL)	26	40	26	50	22	40
Other cHL (% among cHL)	11	13	6	5	19	5
Cumulative incidence [% (95% CI)]	All	cHL	All	cHL (ABVDeq)	All	cHL
at 10 years	NA	2.5 (2.0-3.0)	3.6 (2.5-4.8)	3.0 (2.0-4.3)	2.7 (1.9-3.6)	2.1 (1.5-3.0)
at 15 years	NA	4.3 (3.5-5.1)	5.8 (4.3-7.5)	5.0 (3.5-6.9)	4.0 (3.0-5.2)	3.2 (2.3-3.4)
at 20 years	NA	6.9 (5.0-8.9)	7.9 (5.9-10.3)	7.2 (5.0-9.8)	5.4 (4.0-7.2)	~4.0 (NA - NA)
at 25 years	NA	NA	9.6 (7.1-12.6)	9.2 (6.2-12.8)	NA	NA
at 30 years	NA	NA	12.2 (8.6-16.4)	13.6 (7.4-21.7)	NA	NA

*Potential maximal follow-up 37 years

Pts=patients, CR1: first complete remission, VLR: very late relapses, CT: chemotherapy, RT: radiotherapy, cHL: classical Hodgkin Lymphoma, NLPHL: nodular lymphocyte predominant Hodgkin lymphoma, NS: nodular sclerosis, MC: mixed cellularity, CMT: combined modality treatment, ABVDeq: ABVD equivalent, 95% CI: 95% Confidence Interval, NA: Not Applicable